Thyroid disease
Conditions
Interventions
Dexmedetomidine combined with nalbuphine group:After thyroidectomy, administer 0.2mg/kg nalbuphine (5ml) intravenously and 0.4ug/kg dexmedetomidine (10ml) by pump for 10 minutes
Dexmedetomidine group:After thyroidectomy, administer 5ml of physiological saline intravenously and 0.4ug/kg dexmedetomidine (10ml) by pump for 10 minutes
Saline group:After thyroidectomy, administer 5ml of physiological saline intravenously and 10ml of physiological saline by pump for 10 minutes
Sponsors
The Second Affiliated Hospital of Shantou University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Selective thyroidectomy; 2. ASA classification levels I-II; 3. Age range: 18-65 years old; 4. BMI<28 kg/m^2; 5. No contraindications for surgical anesthesia.
Exclusion criteria
Exclusion criteria: 1. Patients with severe cardiopulmonary dysfunction; 2. Abnormal coagulation function or liver and kidney function; 3. Individuals who are allergic to the experimental drug; 4. Patients who cough due to the primary disease before surgery; 5. Sinus bradycardia or atrioventricular block; 6. Recent history of severe upper respiratory infections; 7. Long term use of psychotropic drugs and drug addicts.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of agitation during the awakening period;Incidence of coughing during extubation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Wake up time and extubation time;Hemodynamic data;Postoperative pain VAS score;Nausea and vomiting incidence rate;24h postoperative drainage;Postoperative QoR-40 scale score; | — |
Countries
China
Contacts
Public ContactLi Li
The Second Affiliated Hospital of Shantou University School of Medicine
Outcome results
None listed